PCOS and GLP-1 Weight Loss: What Younger Women Should Know

If you are in your 20s or 30s and weight has become harder to lose, you are far from alone. Polycystic ovary syndrome, or PCOS, is one of the most common hormonal conditions in women of this age, and weight is one of the things many women with it struggle with most. This article explains, in plain terms, what PCOS has to do with weight, where GLP-1 medicines like Mounjaro and Wegovy fit in, who they may suit, and how the consultation works. It is general information, not a diagnosis or a treatment plan.

What PCOS has to do with weight

PCOS affects how the ovaries work and how the body handles hormones. Many, though not all, women with PCOS have higher insulin levels, sometimes called insulin resistance. Insulin is the hormone that helps the body store energy. When it runs high, the body can find it easier to store fat and harder to release it, which is one reason weight can feel stuck despite real effort with diet and exercise.

This is worth saying plainly: if you have PCOS and weight has been hard to shift, that is not a failure of willpower. The biology is genuinely different. PCOS is also linked to a higher chance of prediabetes and type 2 diabetes over time, which is part of why weight is taken seriously in its management. Any decision about PCOS itself should be made with your GP or specialist.

Where GLP-1 medicines fit in

GLP-1 medicines such as Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only treatments licensed to support weight loss in suitable adults. They work mainly by reducing appetite and quietening the constant background hunger that many people describe as food noise. They are not a quick fix, and they are not right for everyone.

It is important to be clear about what these medicines are and are not. They are weight loss treatments. They are not a treatment for PCOS itself, and they are not a fertility treatment. Some women with PCOS who lose weight do notice other changes, but that is not something we can promise, and any effect on PCOS symptoms should be discussed with the clinician who looks after your PCOS. What GLP-1 treatment is licensed to do is support weight loss when you are eligible and it is prescribed and supervised properly.

In clinical trials at 72 weeks, Mounjaro produced an average 22.5% reduction in body weight and Wegovy an average of 20.7%. These are trial averages, not a guarantee, and individual results vary with your starting weight, your dose, your lifestyle and how long you stay on treatment.

Who GLP-1 treatment may suit

Eligibility in the UK is based on clinical criteria, not on having PCOS. There are two routes:

• A BMI of 30 or above, or
• A BMI between 27 and 29.9 together with at least one weight-related health condition

PCOS is one of the recognised weight-related conditions a prescriber will take into account, alongside others such as high blood pressure, prediabetes and high cholesterol. You do not need a formal PCOS diagnosis to be considered, and PCOS on its own does not lower the BMI thresholds. You declare your conditions and medicines during the consultation, and the pharmacist reviews them together.

Who should not take these medicines

Some people should not take GLP-1 medication even if their BMI qualifies. The main exclusions include:

• Anyone under 18
• Pregnancy, trying to conceive, or breastfeeding
• A personal or family history of medullary thyroid cancer or MEN2, a rare endocrine condition
• A history of pancreatitis
• Certain gut, gallbladder and eating disorders, assessed case by case

The point about conception matters for many younger women. If you have PCOS and are trying for a baby, or you could become pregnant, tell the pharmacist. GLP-1 medicines are not suitable in pregnancy, and you should discuss contraception and timing openly so the advice you get is safe.

The consultation route

The process is designed to be simple and safe. You complete an online consultation with your height, weight, medical history and current medicines. If you have PCOS, you tell us there. You then book a video consultation with the prescribing pharmacist. There is no charge to book, and you only pay for treatment if it is approved on your call. You do not pay for medication you cannot have.

Every consultation is reviewed personally by a GPhC-registered pharmacist. There is no automated approval. If treatment is not right for you, they will tell you plainly and explain why, and may suggest speaking to your GP or another route instead. A refusal is an honest clinical answer, not a dead end.